Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines

Pancreatic ductal adenocarcinoma is a devastating disease with a 5-year overall survival of 9% for all stages. Gemcitabine-based chemoradiotherapy for locally advanced pancreatic cancer is highly toxic. We conducted an in vitro study to determine whether poly(ADP-ribose) polymerase-1 inhibition radi...

Descripción completa

Detalles Bibliográficos
Autores principales: Waissi, Waisse, Amé, Jean-Christophe, Mura, Carole, Noël, Georges, Burckel, Hélène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269291/
https://www.ncbi.nlm.nih.gov/pubmed/34201963
http://dx.doi.org/10.3390/ijms22136825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269291/
https://www.ncbi.nlm.nih.gov/pubmed/34201963
http://dx.doi.org/10.3390/ijms22136825

Ejemplares similares